A new research article in *Cardiovascular Innovations and Applications* highlights the comparable effectiveness of potassium-competitive acid blockers (P-CABs) and proton pump inhibitors (PPIs) in averting upper gastrointestinal bleeding (UGIB) among patients receiving dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). DAPT, while essential after PCI, carries an elevated risk of UGIB. PPIs are commonly prescribed for gastroprotection, but their slow action and potential interactions with clopidogrel pose limitations, suggesting a need for alternatives. P-CABs offer a promising solution with their ability to provide rapid and consistent acid suppression.
This comprehensive systematic review and meta-analysis synthesized data from six observational cohort studies, encompassing 42,304 patients, published up to March 2026. The findings revealed no significant difference in the incidence of UGIB between patients treated with P-CABs and those receiving PPIs (odds ratio 1.03, 95% confidence interval 0.77-1.37; I2 = 4%). A sensitivity analysis, which excluded studies with a high risk of bias, reinforced these consistent results (odds ratio 0.96, 95% confidence interval 0.70-1.30). Furthermore, the study observed no notable differences in major adverse cardiovascular events or overall mortality between the two treatment groups. Despite these encouraging results, the certainty of the evidence was rated as very low, primarily due to potential confounding factors and imprecision in the observational studies.
While P-CABs appear to offer a similar protective effect against UGIB as PPIs in this patient population, the current body of evidence necessitates further investigation. The authors emphasize the critical need for well-designed randomized controlled trials to definitively establish the comparative efficacy and safety of P-CABs against PPIs in patients undergoing DAPT after PCI. Such trials would provide higher-quality evidence to guide clinical practice and optimize gastroprotection strategies, ultimately improving patient outcomes.
The pursuit of innovative medical solutions and rigorous scientific inquiry consistently advances patient care, reinforcing the commitment to better health outcomes and effective therapeutic strategies.
